Advertisement

Pneumonologie

, Volume 151, Issue 3, pp 167–184 | Cite as

Ethionamide+Cycloserine+PAS vs Isoniazid+Streptomycin+PAS in Initial Antituberculosis Chemotherapy Followed by the Standard Regimen A Controlled Study with Special Reference to the Microscopic Enumeration of Bacilli as a Criterion of Efficacy

Article
  • 36 Downloads

Keywords

Public Health Streptomycin Special Reference Isoniazid Standard Regimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anastasatu, C., Bercea, O., Marcian, S., Ceicu, A.: Das bakteriologische Syndrom „Smearpositives Kultur-negatives” Sputum während der Rifampicin-Behandlung. Pneumonologie, Suppl. 52–53 (1970)Google Scholar
  2. Anonym: Drugs1, 349–398 (1971)Google Scholar
  3. Anonym: Tuberculose: Un traitement considérablement modific. Sem. Hop.47, Inform. 16–18 (1971)Google Scholar
  4. Auersbach, K., Bartmann, K., Kauffmann, G.-W., Krebs, A., Schütz, I., Steinbrück, P.: Die frühe Erkennung des ungenügenden Effekts der konservativ-chemischen Behandlung bei kavernöser Lungentuberkulose. Fortschr. Tuberk. Forsch.11, 122–192 (1961)Google Scholar
  5. Bartmann, K.: Zur Methodik der klinischen Prüfung von Antituberculotica. 5th. Internat. Congr. of Chemotherapy, Vienna, 26 June–1 July 1967, pp. 5–18Google Scholar
  6. Bergamini, N., Bachini, V., Ferrario, G., Fowst, G.: Rifampicin: A clinical survey. Arzneimittel-Forsch.20, 1546–1551 (1970)Google Scholar
  7. British Medical Research Council Co-operative Study (1973) Tubercle54, 99 (1973)Google Scholar
  8. Canetti, G.: Modifications des populations des foyers tuberculeux au cours de la chimiotherapie antibacillaire. Ann. Inst. Pasteur97, 53–79 (1959)Google Scholar
  9. Corpe, R. F., Blalock, F. A.: Analysis of the fate of patients with open-negative syndrome. Amer. Rev. resp. Dis.85, 870–882 (1962)Google Scholar
  10. Corpe, R. F., Blalock, F. A.: A continuing study of patients with “open-negative” status of Battey State Hospital. Amer. Rev. resp. Dis.98, 954–964 (1968)Google Scholar
  11. Eule, H.: Die Ätinabehandlung der chronischen Lungentuberkulose. Z. Tuberk.122, 122–126 (1964)Google Scholar
  12. Eule, H., Ewert, E. G.: Die Bedeutung der Restkavernen nach erreichter Sputumkonversion. Beitr. Klin. Tuberk.133, 323–335 (1966)Google Scholar
  13. Haegi, V.: Die Kombinationsbehandlung der Lungentuberkulosen mit Rifampizin und Ethambutol. Helvetica Medica Acta, Suppl.49, 81–87 (1969)Google Scholar
  14. Hobby, G. L., Johnson, P. M., Crawford-Gagliardi, L., Boytar, V., Johnson, G. E.: Primary drug resistance. A continuing study of drug resistance in tuberculosis in a veteran population within the United States. Amer. Rev. resp. Dis.94, 703–708 (1966)Google Scholar
  15. Hobby, G. L., Johnson, P. M., Boytar-Papirnyk, V.: Primary drug resistance: A continuing study of drug resistance in tuberculosis in a veteran population in the United States — September 1962 to September 1971. Trans. 31st. Res. Conf. Pulm. Dis. VA-Armed Forces (Cincinnati, Ohio) 36–41 (1972)Google Scholar
  16. Hofmann, F.: Monotherapie chronischer Lungentuberkulosen mit Rimactan. Schweiz. med. Wschr.98, 1363–1367 (1968)Google Scholar
  17. Holman, A. P., Iseman, M., Jones, J. M., Hobby, G. L.: A microscopic technique for quantitation of tubercle bacilli in sputum. Trans. 31st Res. Conf. Pulm. Dis. VA-Armed Forces (Cincinnati, Ohio), 5–7 (1972)Google Scholar
  18. Horne, N. M.: Drug-resistant tuberculosis. A review of the world situation. Tubercle (Edinb.), Suppl.50, 2–12 (1969)Google Scholar
  19. Iseman, M. D., Holman, A. P., Jones, J. M., Hobby, G. L.: Evaluation of therapeutic responses to chemotherapy of tuberculosis by a quantitative microscopic technique. Trans. 31st Res. Conf. Pulm. Dis. VA-Armed Forces (Cincinnati, Ohio), 8–11 (1972)Google Scholar
  20. Jančik, E.: Effects des agents antibacillaires dits secondaires sur la tuberculose pulmonaire. Fortschr. Tuberk. Forsch.13, 121–128 (1964)Google Scholar
  21. Kumagai, T., Oka, S., Suzuki, C., Kurobane, T., Sato, S., Awataguoai, S., Nutsu, Y., Kumagai, T., Ueta, H., Ichinomya, M., Shoji, M., Ashizawa, H., Ishida, H.: Sci. Rep. Res. Inst. Tohoku Univ. C. 8, Suppl. (1958)Google Scholar
  22. Laumen, F.: Monotherapie und Kombinationstherapie mit Rifampicin bei 156 Tuberkuloseerkrankungen. Prax. Pneumol.24, 158–168 (1970)Google Scholar
  23. Lee, C. S.: Clinical effect of Rifampicin. Tuberculosis and Respiratory Dis. (Korea)19, 30–34 (1972)Google Scholar
  24. Lees, A. W.et al. Toxicity from Rifampicin plus Isoniazid and Rifampicin plus Ethambutol therapy. Tubercle (Edinb.)52, 182–190 (1971)Google Scholar
  25. Lucchesi, M., Mancini, P.: Antimycobacterial activity of Rifampicin Antibiotica et Chemotherapia16, 431–443 (1969)Google Scholar
  26. Lukas, W.: Analytical study of the treatment of 18 cases of chronic open pulmonary tuberculosis with secondary resistance to Rifampicin. Respiration28, suppl. 70–83 (1971)Google Scholar
  27. Müller, W.: Zur Therapie chronischer Lungentuberkulosen. Fortschr. Med.89, 1143–1147 (1971)Google Scholar
  28. Pätiälä, J., Tani, P.: Gegenwärtiger Stand der Chemotherapie der Lungentuberkulose in Finnland. Prax. Pneumol.25, 677–685 (1971)Google Scholar
  29. Puech, P., Schlesinger, P. A., Sauvaget, M.: L'évolution radiologique des cavernes tuberculeuses du poumon sous chimiothérapie. Fortschr. Tuberk. Forsch.13, 325–385 (1964)Google Scholar
  30. Radenbach, K. L.: Behandlung und Behandlungsergebnisse bei Tuberkulosekranken mit sekundärer Bakterienresistenz. Proc. IIIrd Internat. Congr. Chemother., Stuttgart 1963, vol. 1, pp. 130–143. (Stuttgart: Thieme 1964)Google Scholar
  31. Radenbach, K. L.: Therapeutic possibilities of minor antibacterial drugs against infections with Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy — 1965, pp. 1065–1073. American Society for Microbiology, Ann Arbor, Michigan 1966Google Scholar
  32. Raleigh, J. W.: Rifampicin in treatment of advanced pulmonary tuberculosis: Report of Rifampicin pilot study 2. Trans. 30th Res. Conf. Pulm. Dis. VA-Armed Froces (Cincinnati, Ohio), 57–61 (1971)Google Scholar
  33. Rist, N., Crofton, J.: Drug resistance in hospitals and sanatoria. A report to the Committee on Laboratory Methods and to the Committee on Antibiotics and Chemotherapy of the International Union against Tuberculosis. Bull. Un. int. Tuberc.30, 2–44 (1960)Google Scholar
  34. Schriever, O.: Die derzeitige Häufigkeit der primären und sekundären Resistenz gegen Antituberculotica. Prax. Pneumol.27, 145–149 (1973)Google Scholar
  35. Schütz, I., Bartmann, K.: Ethionamid in Zweier- oder Dreierkombination bei chronischer, vorbehandelter Lungentuberkulose. Prax. Pneumol.18, 288–298 (1964)Google Scholar
  36. Schütz, I., Bartmann, K.: A controlled clinical trial of ethionamide (ETH) + cycloserine (CS) + PAS 6 times weekly versus 4 times weekly in the first phase of clinical retreatment. 18th Internat. Tuberc. Conf. Munich, 5–9 Oct., Exc. Med.96, 114 (1965)Google Scholar
  37. Sighart, H., Opl, G., Benkö, M.: Rifampicin in der Behandlung der chronischen Lungentuberkulose. Wien. klin. Wschr.82, 693–696 (1970)Google Scholar
  38. Steenken, W., j., Meade, G. M., Wolinsky, E., Coates, j. E. O.: Demonstration of increased drug resistance of tubercle bacilli from patients treated with hydrazines of isonicotinic acid. Amer. Rev. resp. Dis.65, 754–758 (1952)Google Scholar
  39. Virchow, Chr., Flemming, J.: Clinical results of Rifampicin treatment. Antibiotica et Chemotherapia16, 471–479 (1969)Google Scholar
  40. Vishwanathanet al. Ind. J. Med. Res.58, 519 (1970), zit.: Rifampicin, A Review. Drugs1, 349–398 (1971)Google Scholar
  41. Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten (W. A. T. L.): Kooperative, kontrollierte Prüfung von Thiocarlid (DATC), PAS und Bettruhe in kurzfristiger Monotherapie bei kavernöser vorbehandelter Lungentuberkulose. Beitr. Klin. Tuberk.139, 115–139 (1969)Google Scholar
  42. Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten (Working Group for Cooperative Studies on Chemotherapy of Respiratory Diseases): A comparison of INH+SM+PAS (ISP) vs INH+RMP+EMB (IRE) in the initial intensive phase of primary chemotherapy with special reference to hepatotoxicity. XXIInd Internat. Tuberc. Conf., Tokyo, 24.–28. Sept. 1973Google Scholar
  43. Zierski, M.: Retreatment of pulmonary tuberculosis in patients with bacilli resistant to major drugs. Optimal regimens. Bull. Un. int. Tuberc.35, 173–178 (1964)Google Scholar
  44. Zierski, M.: Persistent post-tuberculosis cavities (“open-negative syndrome”) after chemotherapy of pulmonary tuberculosis: A co-operative follow-up study. Tubercle (Edinb.)47, 394–400 (1966)Google Scholar

Copyright information

© Springer-Verlag 1975

Personalised recommendations